Intercytex Group
Cambridge
About Intercytex Group
Intercytex Group plc, a development stage biotechnology company, engages in the research, development, and commercialization of cell-based therapies for the repair and regeneration of skin and hair. The company, using its integrated cell technology platform, develops living, human cell-based products. Its product programs in development include VAVELTA, a facial rejuvenation and skin damage repair product, which completed Phase II trials; SHEF-1-Stem Cell Line, which would develop a cure for AMD, the leading cause of blindness in the elderly; ICX-TRC, a hair regeneration product that completed Phase II trials; and ICX-SKN, a skin graft replacement for burns and acute wounds, which completed Phase I trial. The company was founded in 2000 and is headquartered in Cambridge, the United Kingdom.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $43.2M
- Last round: Series Unknown (Sep 2008)
- Website: intercytex.com
- Phone: [email protected]
Industries & Categories
Beauty, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/intercytex-group-2429320 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.